Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epigallocatechin gallate + copper + bacillus Calmette-Guérin
- Development stage
- Preclinical
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravesical
01
Overview
epigallocatechin gallate + copper + bacillus Calmette-Guérin (EGCG-Cu@BCG) is a novel synergistic metal-phenolic nanomaterial complex developed for the treatment of bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC). It is synthesized by coating the surface of Bacillus Calmette-Guérin (BCG) with an epigallocatechin gallate-copper (EGCG-Cu) coordination complex via a gentle physical incubation method. EGCG-Cu@BCG is designed to overcome the limitations of BCG monotherapy, such as limited direct tumor-killing ability and variable immune activation, by combining the direct cytotoxic effects of EGCG-Cu with the immunoadjuvant properties of BCG. The complex induces tumor cell apoptosis, mitochondrial membrane potential decrease, and strong immunogenic cell death (ICD), characterized by calreticulin (CRT) exposure on the cell membrane and high mobility group box 1 (HMGB1) release from the nucleus. In preclinical mouse models of bladder cancer, intravesical administration of EGCG-Cu@BCG has demonstrated enhanced anti-tumor efficacy and reduced tumor recurrence without significant systemic toxicity.
- Other names
- EGCG-Cu@BCGEGCG-Cu@BCG complexepigallocatechin gallate-copper complex coated bacillus Calmette-Guérin
Beyond the preview
Go deeper on epigallocatechin gallate + copper + bacillus Calmette-Guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epigallocatechin gallate + copper + bacillus Calmette-Guérin.